Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.
Anandamide (AEA) is an endogenous cannabinoid ligand acting predominantly on the cannabinoid 1 (CB(1)) receptor, but it is also an agonist on the capsaicin VR(1)/TRPV(1) receptor. In the present study we examined the effects of AEA and the naturally occurring cannabinoid 2 (CB(2)) receptor agonist palmitylethanolamide (PEA) on basal and resiniferatoxin (RTX)-induced release of calcitonin gene-related peptide (CGRP) and somatostatin in vivo. Since these sensory neuropeptides play important role in the development of neuropathic hyperalgesia, the effect of AEA and PEA was also examined on mechanonociceptive threshold changes after partial ligation of the sciatic nerve. Neither AEA nor PEA affected basal plasma peptide concentrations, but both of them inhibited RTX-induced release. The inhibitory effect of AEA was prevented by the CB(1) receptor antagonist SR141716A. AEA abolished and PEA significantly decreased neuropathic mechanical hyperalgesia 7 days after unilateral sciatic nerve ligation, which was antagonized by SR141716A and the CB(2) receptor antagonist SR144528, respectively. Both SR141716A and SR144528 increased hyperalgesia, indicating that endogenous cannabinoids acting on CB(1) and peripheral CB(2)-like receptors play substantial role in neuropathic conditions to diminish hyperalgesia. AEA and PEA exert inhibitory effect on mechanonociceptive hyperalgesia and sensory neuropeptide release in vivo suggesting their potential therapeutical use to treat chronic neuropathic pain.
Helyes
Zsuzsanna
Z
Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, H-7624, Pécs, Szigeti u. 12, Hungary. zsuzsanna.helyes@aok.pte.hu
Németh
József
J
Thán
Márta
M
Bölcskei
Kata
K
Pintér
Erika
E
Szolcsányi
János
J
D000577:Amides; D000818:Animals; D001095:Arachidonic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000097:blood / Q000378:metabolism; D001892:Camphanes / Q000494:pharmacology; D002186:Cannabinoids / Q000008:administration & dosage / Q000494:pharmacology*; D004224:Diterpenes / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D004983:Ethanolamines; D006930:Hyperalgesia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007275:Injections, Intravenous; D008297:Male; D009479:Neuropeptides / Q000097:blood / Q000378:metabolism*; D009498:Neurotoxins / Q000633:toxicity; D010169:Palmitic Acids / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D000077285:Rimonabant; D012584:Sciatic Nerve / Q000293:injuries / Q000473:pathology; D020426:Sciatic Neuropathy / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013004:Somatostatin / Q000097:blood / Q000378:metabolism
D000577:Amides; D001095:Arachidonic Acids; D001892:Camphanes; D002186:Cannabinoids; D004224:Diterpenes; D063388:Endocannabinoids; D004983:Ethanolamines; D009479:Neuropeptides; D009498:Neurotoxins; D010169:Palmitic Acids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; C110630:SR 144528; D013004:Somatostatin; C005958:palmidrol; C024353:resiniferatoxin; D015740:Calcitonin Gene-Related Peptide; D000077285:Rimonabant; C078814:anandamide